£50.0M
NRG Therapeutics raises £50m in Series B funding to advance mitochondrial drugs into clinical trials
The financing round was led by SV Health Investors and will fund initial human trials for the company lead candidate in ALS and Parkinson's.
NT
NRG Therapeutics
NRG Therapeutics develops mitochondrial-targeted treatments for neurodegenerative conditions.
Stevenage, UK—Founded 2018
£50.0MTotal raised
Stevenage-based biotechnology company developing small molecule therapeutics to target mitochondrial dysfunction in neurodegenerative diseases.
Filed accounts
Cash at bank
Members only
Net current assets
Members only
Total assets less current liabilities
Members only
Net assets
Members only
Shareholders' funds
Members only
Fixed assets
Members only
Cash, assets and headcount from NRG Therapeutics's latest Companies House filing — with year-on-year movement, free with a Winfred account.
Categories
Founders
NM
Neil Miller
CEO
Neil brings senior executive and drug discovery experience from roles at GlaxoSmithKline, Auspherix, and NRG Therapeutics. He serves as co-founder and chief executive officer of NRG Therapeutics.
LinkedInRR
Richard Rutter
CSO
Richard brings drug discovery and biotech experience from roles at GlaxoSmithKline and as a founder and chief scientific officer at NRG Therapeutics.
LinkedInGH
Grant Hawthorn
COO